Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial

BACKGROUND AND AIMS: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. We present primary completion analysis from RIVETING, an ongoing, double-blind, randomised, parallel-group trial evaluating efficacy and safety of tofacitinib dose reduction to...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Crohns Colitis
Главные авторы: Vermeire, Séverine, Su, Chinyu, Lawendy, Nervin, Kobayashi, Taku, Sandborn, William J, Rubin, David T, Modesto, Irene, Gardiner, Sean, Kulisek, Nicole, Zhang, Haiying, Wang, Wenjin, Panés, Julian
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2020
Предметы:
Original Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8256630/
https://ncbi.nlm.nih.gov/pubmed/33290538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jjaa249
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы